24 results on '"Fuchs, Michael"'
Search Results
2. Interaction of bacterial metagenome and virome in patients with cirrhosis and hepatic encephalopathy.
- Author
-
Bajaj, Jasmohan S., Sikaroodi, Masoumeh, Shamsaddini, Amirhossein, Henseler, Zachariah, Santiago-Rodriguez, Tasha, Acharya, Chathur, Fagan, Andrew, Hylemon, Phillip B., Fuchs, Michael, Gavis, Edith, Ward, Tonya, Knights, Dan, and Gillevet, Patrick M.
- Subjects
CIRRHOSIS of the liver ,HEPATIC encephalopathy ,STREPTOCOCCUS ,ALCOHOLIC liver diseases ,CLOSTRIDIUM diseases - Published
- 2021
- Full Text
- View/download PDF
3. Fecal Microbiota Transplant in Cirrhosis Reduces Gut Microbial Antibiotic Resistance Genes: Analysis of Two Trials.
- Author
-
Bajaj, Jasmohan S., Shamsaddini, Amirhossein, Fagan, Andrew, Sterling, Richard K., Gavis, Edith, Khoruts, Alexander, Fuchs, Michael, Lee, Hannah, Sikaroodi, Masoumeh, and Gillevet, Patrick M.
- Subjects
GUT microbiome ,CIRRHOSIS of the liver - Abstract
Antibiotic resistance leads to poor outcomes in cirrhosis. Fecal microbiota transplant (FMT) is associated with reduction in antibiotic resistance gene (ARG) burden in patients without cirrhosis; however, the impact in cirrhosis is unclear. We aimed to study the effect of capsule and enema FMT on ARG abundance in fecal samples, which were collected during two published FMT trials in patients with cirrhosis on rifaximin, lactulose, and proton pump inhibitors. ARGs were identified using metagenomics and mapped against the Comprehensive Antibiotic Resistance Database. Changes in ARG abundance were studied within/between groups. The capsule FMT trial involved a one‐time FMT or placebo capsule administration with stool collection at baseline and week 4 postintervention. Antibiotics+enema FMT included preprocedure antibiotics followed by FMT enema versus standard‐of‐care (SOC). Stool was collected at baseline, postantibiotics, and day 7/15 postintervention. Both trials included 20 patients each. There was no safety/infection signal linked to FMT. In the capsule trial, beta‐lactamase (OXY/LEN) expression decreased post‐FMT versus baseline. Compared to placebo, patients who were post‐FMT had lower abundance of vancomycin (VanH), beta‐lactamase (ACT), and rifamycin ARGs; the latter was associated with cognitive improvement. No changes were seen within patients treated with placebo. In the antibiotics+enema trial for postantibiotics at day 7 versus baseline, there was an increase in vancomycin and beta‐lactamase ARGs, which decreased at day 15. However, quinolone resistance increased at day 15 versus baseline. Between SOC and FMT, day 7 had largely lower ARG (CfxA beta‐lactamase, VanW, and VanX) that continued at day 15 (cepA beta‐lactamase, VanW). No changes were seen within the SOC group. Conclusion: Despite differences in routes of administration and preintervention antibiotics, we found that ARG abundance is largely reduced after FMT compared to pre‐FMT baseline and non‐FMT groups in decompensated cirrhosis. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
4. Cognition and hospitalizations are linked with salivary and faecal microbiota in cirrhosis cohorts from the USA and Mexico.
- Author
-
Bajaj, Jasmohan S., Torre, Aldo, Rojas, Mayra L., Fagan, Andrew, Nandez, Ivvone E., Gavis, Edith A., De Leon Osorio, Omar, White, Melanie B., Fuchs, Michael, Sikaroodi, Masoumeh, and Gillevet, Patrick M.
- Subjects
CIRRHOSIS of the liver ,LOW-protein diet ,NUTRITION counseling ,HOSPITAL care ,HEPATIC encephalopathy - Abstract
Background & Aims: Gut microbiota are affected by diet and ethnicity, which impacts cognition and hospitalizations in cirrhosis. Aim: Study interactions of diet with microbiota and impact on hospitalizations and cognition in American and Mexican cohorts. Methods: Controls and age‐balanced patients with compensated/decompensated cirrhosis were included and followed for 90‐day hospitalizations. A subset underwent minimal hepatic encephalopathy (MHE) testing. Parameters such as dietary, salivary and faecal microbiota (diversity, taxa analysis, cirrhosis dysbiosis ratio CDR:high = good) between/within countries were analysed. Regression analyses for hospitalizations and MHE were performed. Results: In all, 275 age‐balanced subjects (133 US [40 Control, 50 Compensated, 43 Decompensated] and 142 Mexican [41 Control, 49 Compensated, 52 Decompensated]) were enrolled. MELD/cirrhosis severity was comparable. Diet showed lower protein and animal fat intake in all decompensated patients, but this was worse in Mexico. Diversity was lower in stool and saliva in decompensated patients, and worse in Mexican cohorts. Prevotellaceae were lower in decompensated cirrhosis, particularly those with lower animal fat/protein consumption across countries. Hospitalizations were higher in Mexico vs the USA (26% vs 14%, P =.04). On regression, Prevotellaceae, Ruminococcaceae and Lachnospiraceae lowered hospitalization risk independent of MELD and ascites. MHE testing was performed in 120 (60/country and 20/subgroup) subjects and MHE rate was similar. MELD and decompensation increased while CDR and Prevotellaceae decreased the risk of MHE. Conclusions: Changes in diet and microbiota, especially related to animal fat and protein intake and Prevotellaceae, are associated with MHE and hospitalizations in Mexican patients with cirrhosis compared to an American cohort. Nutritional counselling to increase protein intake in cirrhosis could help prevent these hospitalizations. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
5. Serum and urinary metabolomics and outcomes in cirrhosis.
- Author
-
Bajaj, Jasmohan S., Fan, Sili, Thacker, Leroy R., Fagan, Andrew, Gavis, Edith, White, Melanie B., Heuman, Douglas M., Fuchs, Michael, and Fiehn, Oliver
- Subjects
AMINO acid metabolism ,METABOLOMICS ,ASCITIC fluids ,SATURATED fatty acids ,SERUM ,CIRRHOSIS of the liver ,HEPATIC encephalopathy - Abstract
Background: Cirrhosis can alter several metabolic pathways. Metabolomics could prognosticate outcomes like hepatic encephalopathy (HE), transplant, hospitalization and death. Aim: Determine changes in serum and urine metabolomics in cirrhotics who develop outcomes. Methods: Cirrhotic outpatients underwent data, serum/urine collection and were followed for 90 days. Demographics, cirrhosis details and medications were collected. Metabolomics was performed on urine/serum using GC/MS with subsequent bioinformatics analyses (ChemRICH, MetaMAPP and PLS-DA). Logistic regression adjusting for covariates (demographics, alcohol etiology, prior HE, PPI, SBP prophylaxis, rifaximin/lactulose) were performed and ROC curves comparing MELD to adjusted serum & urine metabolites were created. Results: 211 patients gave serum, of which 64 were hospitalized, 19 developed HE, 13 were transplanted and 11 died. 164 patients gave urine of which 56 were hospitalized, 18 developed HE, 12 were transplanted and 11 died. : Saturated fatty acids, amino acids and bioenergetics-related metabolites differentiated patients with/without outcomes. After regression, 232, 228, 284 and 229 serum metabolites were significant for hospitalization, HE, death and transplant. In urine 290, 284, 227 & 285 metabolites were significant for hospitalization, HE, death and transplant respectively. AUC was higher for serum metabolites vs MELD for HE (0.85 vs.0.76), death (0.99 vs.0.88), transplant (0.975 vs.0.94) and hospitalizations (0.84 vs.0.83). Similarly, urinary metabolite AUC was also higher than MELD for HE (0.87 vs.0.72), death (0.92 vs 0.86), transplant (0.99 vs.0.90) and hospitalizations (0.89 vs.0.84). Conclusions: In this exploratory study, serum and metabolites focused on lipid, bioenergetics and amino acid metabolism are altered in cirrhotics who develop negative outcomes. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
6. Effect of Post-Traumatic Stress Disorder on Cognitive Function and Covert Hepatic Encephalopathy Diagnosis in Cirrhotic Veterans.
- Author
-
Burroughs, Thomas K., Wade, James B., Ellwood, Michael S., Fagan, Andrew, Heuman, Douglas M., Fuchs, Michael, and Bajaj, Jasmohan S.
- Subjects
HEPATIC encephalopathy ,INHIBITORY postsynaptic potential ,PSYCHIATRIC drugs ,COGNITIVE ability ,CIRRHOSIS of the liver ,COGNITION ,COMPARATIVE studies ,VETERANS ,RESEARCH methodology ,MEDICAL cooperation ,MULTIVARIATE analysis ,POST-traumatic stress disorder ,RESEARCH ,RESEARCH funding ,LOGISTIC regression analysis ,EVALUATION research ,DISEASE complications - Abstract
Background: In veterans, post-traumatic stress disorder (PTSD) is often associated with substance abuse, which in turn can lead to cirrhosis. Cirrhotic patients are prone to cognitive impairment, which is typically due to covert hepatic encephalopathy (CHE), but can also be affected by PTSD. The aim was to define the impact of PTSD on cognitive performance and the diagnosis of CHE in cirrhotic patients.Methods: Outpatient veterans with cirrhosis underwent two separate modalities for CHE cognitive testing [Psychometric Hepatic Encephalopathy Scale (PHES) and Inhibitory Control Test (ICT)]. ICT tests for inhibitory control and response inhibition, while PHES tests for attention and psychomotor speed. Comparisons were made between patients with/without PTSD. Multivariable logistic regression with CHE on PHES and CHE on ICT as dependent variables including prior OHE, demographics, PTSD and psychotropic medications was performed.Results: Of 402 patients with cirrhosis, 88 had evidence of PTSD. Fifty-five of these were on psychoactive medications, 15 were undergoing psychotherapy, while no specific PTSD-related therapy was found in 28 patients. Cirrhotic patients with/without PTSD were statistically similar on demographics and cirrhosis severity, but cirrhotic subjects with PTSD had a higher frequency of alcoholic cirrhosis etiology and psychotropic drug use. PTSD cirrhosis had higher ICT lure and switching errors (NCT-B response), but on regression, there was no significant impact of PTSD on CHE diagnosis using either the ICT or PHES.Conclusions: Veterans with cirrhosis and PTSD have a higher frequency of psychotropic drug use and alcoholic cirrhosis etiology. CHE diagnosis using PHES or ICT is not affected by concomitant PTSD. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
7. Symptom Domain Groups of the Patient-Reported Outcomes Measurement Information System Tools Independently Predict Hospitalizations and Re-hospitalizations in Cirrhosis.
- Author
-
Patidar, Kavish, Thacker, Leroy, Wade, James, White, Melanie, Gavis, Edith, Fagan, Andrew, Sterling, Richard, Fuchs, Michael, Siddiqui, Mohammad, Matherly, Scott, Stravitz, Richard, Sanyal, Arun, Puri, Puneet, Luketic, Velimir, Bajaj, Jasmohan, Patidar, Kavish R, Thacker, Leroy R, Wade, James B, White, Melanie B, and Gavis, Edith A
- Subjects
CIRRHOSIS of the liver ,HOSPITAL care ,QUALITY of life ,PRINCIPAL components analysis ,PATIENTS ,PROGNOSIS ,HEALTH status indicators ,RESEARCH funding ,SURVEYS ,COMPUTER-aided diagnosis - Abstract
Background: Patient-Reported Outcomes Measurement Information System (PROMIS) tools can identify health-related quality of life (HRQOL) domains that could differentially affect disease progression. Cirrhotics are highly prone to hospitalizations and re-hospitalizations, but the current clinical prognostic models may be insufficient, and thus studying the contribution of individual HRQOL domains could improve prognostication.Aim: Analyze the impact of individual HRQOL PROMIS domains in predicting time to all non-elective hospitalizations and re-hospitalizations in cirrhosis.Methods: Outpatient cirrhotics were administered PROMIS computerized tools. The first non-elective hospitalization and subsequent re-hospitalizations after enrollment were recorded. Individual PROMIS domains significantly contributing toward these outcomes were generated using principal component analysis. Factor analysis revealed three major PROMIS domain groups: daily function (fatigue, physical function, social roles/activities and sleep issues), mood (anxiety, anger, and depression), and pain (pain behavior/impact) accounted for 77% of the variability. Cox proportional hazards regression modeling was used for these groups to evaluate time to first hospitalization and re-hospitalization.Results: A total of 286 patients [57 years, MELD 13, 67% men, 40% hepatic encephalopathy (HE)] were enrolled. Patients were followed at 6-month (mth) intervals for a median of 38 mths (IQR 22-47), during which 31% were hospitalized [median IQR mths 12.5 (3-27)] and 12% were re-hospitalized [10.5 mths (3-28)]. Time to first hospitalization was predicted by HE, HR 1.5 (CI 1.01-2.5, p = 0.04) and daily function PROMIS group HR 1.4 (CI 1.1-1.8, p = 0.01), independently. In contrast, the pain PROMIS group were predictive of the time to re-hospitalization HR 1.6 (CI 1.1-2.3, p = 0.03) as was HE, HR 2.1 (CI 1.1-4.3, p = 0.03).Conclusions: Daily function and pain HRQOL domain groups using PROMIS tools independently predict hospitalizations and re-hospitalizations in cirrhotic patients. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
8. Cirrhotic patients have good insight into their daily functional impairment despite prior hepatic encephalopathy: comparison with PROMIS norms.
- Author
-
Bajaj, Jasmohan, White, Melanie, Unser, Ariel, Ganapathy, Dinesh, Fagan, Andrew, Gavis, Edith, Sterling, Richard, Heuman, Douglas, Matherly, Scott, Puri, Puneet, Sanyal, Arun, Luketic, Velimir, Fuchs, Michael, Siddiqui, Muhammad, Stravitz, R., John, Binu, Thacker, Leroy, and Wade, James
- Subjects
QUALITY of life ,CIRRHOSIS of the liver ,HEPATIC encephalopathy ,LIVER diseases ,HUMAN ecology - Abstract
Health-related quality of life (HRQOL) is an important determinant of prognosis in cirrhosis and hepatic encephalopathy (HE). However due to inherent cognitive dysfunction, insight into HRQOL severity in patients with liver disease may be impaired. To assess insight into HRQOL using PROMIS tools compared to norms in cirrhotic patients. PROMIS tools are validated HRQOL instruments that test the domains of anger, anxiety, depression, physical function, pain behavior/impact, sleep disturbances/impairment, and social activities/roles, compared to US-norms. Patients were administered the PROMIS tools, the results of which were reviewed using a visual comparison with thed norms. Then two Likert scales from 0 to 10 per domain were administered that inquired about (1) Surprise Intensity: 0-4: not surprised, 5-10: surprised; and (2) Expectancies: 0-4: results better than expected, 5:10: as/worse than expected. Comparisons between HE/no-HE were also performed. 203 cirrhotic patients (57 yrs., 62 % men, MELD 12, 83 HE) were included. All HE patients were controlled on therapy. Prior HE patients were significantly impaired on all PROMIS domains ( p < 0.01) except anger, compared to the re st. The majority (76-85 %) were not surprised with their placement vis-à-vis the norms. Similarly, a majority (59-61 %) thought their results were worse or as expected. However, a third of patients found that their PROMIS results were better than expected. Prior HE status did not significantly impact expectations or surprise based on placement with the norms. The majority of cirrhotic patients, regardless of prior HE, have good insight regarding their HRQOL issues. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
9. Enhancement of functional connectivity, working memory and inhibitory control on multi-modal brain MR imaging with Rifaximin in Cirrhosis: Implications for the gut-liver-brain axis.
- Author
-
Ahluwalia, Vishwadeep, Wade, James, Heuman, Douglas, Hammeke, Thomas, Sanyal, Arun, Sterling, Richard, Stravitz, R., Luketic, Velimir, Siddiqui, Mohammad, Puri, Puneet, Fuchs, Michael, Lennon, Micheal, Kraft, Kenneth, Gilles, HoChong, White, Melanie, Noble, Nicole, and Bajaj, Jasmohan
- Subjects
SHORT-term memory ,MAGNETIC resonance imaging of the brain ,CIRRHOSIS of the liver ,HEPATIC encephalopathy ,ANTIBIOTICS ,TREATMENT of endotoxemia ,COGNITION - Abstract
Minimal hepatic encephalopathy (MHE) impairs daily functioning in cirrhosis, but its functional brain impact is not completely understood. To evaluate the effect of rifaximin, a gut-specific antibiotic, on the gut-liver-brain axis in MHE. Hypothesis: Rifaximin will reduce endotoxemia, enhance cognition, increase activation during working memory(N-back) and reduce activation needed for inhibitory control tasks. Methods: Cirrhotics with MHE underwent baseline endotoxin and cognitive testing, then underwent fMRI, diffusion tensor imaging and MR spectroscopy(MRS). On fMRI, two tasks; N-back (outcome: correct responses) and inhibitory control tests(outcomes: lure inhibition) were performed. All procedures were repeated after 8 weeks of rifaximin. Results were compared before/after rifaximin. Results: 20 MHE patients (59.7 years) were included; sixteen completed pre/post-rifaximin scanning with 92 % medication compliance. Pre-rifaximin patients had cognitive impairment. At trial-end, there was a significantly higher correct 2-back responses, ICT lure inhibitions and reduced endotoxemia( p = 0.002). This was accompanied by significantly higher activation from baseline in subcortical structures (thalamus, caudate, insula and hippocampus) and left parietal operculum (LPO) during N-back, decrease in fronto-parietal activation required for inhibiting lures, including LPO during ICT compared to baseline values. Connectivity studies in N-back showed significant shifts in linkages after therapy in fronto-parietal regions with a reduction in fractional anisotropy (FA) but not mean diffusivity (MD), and no change in MRS metabolites at the end of the trial. A significant improvement in cognition including working memory and inhibitory control, and fractional anisotropy without effect on MD or MRS, through modulation of fronto-parietal and subcortical activation and connectivity was seen after open-label rifaximin therapy in MHE. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
10. Covert Hepatic Encephalopathy Is Independently Associated With Poor Survival and Increased Risk of Hospitalization.
- Author
-
Patidar, Kavish R, Sterling, Richard K, Sanyal, Arun J, Siddiqui, Mohammad S, Matherly, Scott C, Stravitz, R Todd, Puri, Puneet, Luketic, Velimir A, Fuchs, Michael, White, Melanie B, Noble, Nicole A, Unser, Ariel B, Gilles, HoChong, Heuman, Douglas M, Bajaj, Jasmohan S, Thacker, Leroy R, and Wade, James B
- Subjects
HEPATIC encephalopathy ,CIRRHOSIS of the liver ,HEPATITIS C ,FATTY liver ,LIVER diseases - Abstract
OBJECTIVES:Despite the high prevalence of covert hepatic encephalopathy (CHE) in cirrhotics without previous overt HE (OHE), its independent impact on predicting clinically relevant outcomes is unclear. The aim of this study was to define the impact of CHE on time to OHE, hospitalization, and death/transplant in prospectively followed up patients without previous OHE.METHODS:Outpatient cirrhotics without OHE were enrolled and were administered a standard paper-pencil cognitive battery for CHE diagnosis. They were systematically followed up and time to first OHE development, hospitalization (liver-related/unrelated), and transplant/death were compared between CHE and no-CHE patients at baseline using Cox regression.RESULTS:A total of 170 cirrhotic patients (55 years, 58% men, 14 years of education, Model for End-Stage Liver Disease (MELD 9), 53% hepatitis C virus (HCV), 20% nonalcoholic etiology) were included, of whom 56% had CHE. The entire population was followed up for 13.0±14.6 months, during which time 30% developed their first OHE episode, 42% were hospitalized, and 19% had a composite death/transplant outcome. Age, gender, etiology, the MELD score, and CHE status were included in Cox regression models for time to first OHE episode, hospitalization, death, and composite death/transplant outcomes. On Cox regression, despite controlling for MELD, those with CHE had a higher risk of developing OHE (hazard ratio: 2.1, 95% confidence interval 1.01-4.5), hospitalization (hazard ratio: 2.5, 95% confidence interval 1.4-4.5), and death/transplant (hazard ratio: 3.4, 95% confidence interval 1.2-9.7) in the follow-up period.CONCLUSIONS:Covert HE is associated with worsened survival and increased risk of hospitalization and OHE development, despite controlling for the MELD score. Strategies to detect and treat CHE may improve these risks. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
11. Driving Simulation Can Improve Insight into Impaired Driving Skills in Cirrhosis.
- Author
-
Bajaj, Jasmohan, Thacker, Leroy, Heuman, Douglas, Gibson, Douglas, Sterling, Richard, Todd Stravitz, R., Fuchs, Michael, Sanyal, Arun, and Wade, James
- Subjects
CIRRHOSIS of the liver ,HEPATIC encephalopathy ,PSYCHOMETRICS ,MEDICAL statistics ,LIKERT scale ,LIVER diseases ,TOXIC psychoses ,SCALE analysis (Psychology) - Abstract
Background: Minimal hepatic encephalopathy (MHE) is associated with poor driving skills and insight. Increasing insight may improve receptiveness for therapy or driving restrictions. Aim: To evaluate the change in the self-assessment of driving skills (SADS) using a driving simulator. Methods: Cirrhotic patients and age/education-matched controls underwent MHE testing with inhibitory control (ICT) and the psychometric hepatic encephalopathy score (PHES). SADS, a Likert scale from 0 to 10, was administered just before and after a standardized driving simulation comprising testing and navigation tasks. The percentage SADS change from baseline was compared within/between groups. Results: A total of 84 patients (60% men, age 55 years) and 12 controls were included. Controls were significantly better than cirrhotics on cognitive/simulator testing. The baseline SADS was similar between the groups. The baseline patient SADS was only correlated with ICT lures ( r = −0.4, P = 0.001). Post-simulation, 60% of patients improved their insight, i.e., reduced SADS (from 8 to 6.5, P = 0.0001) compared to 25% of controls ( P = 0.02). The mean percentage SADS reduction was also higher in cirrhotics (18% vs. 8%, P = 0.03). MHE on ICT patients had a significantly higher SADS improvement ( P = 0.004) compared to the other patients; no difference was seen in those with/without MHE due to the PHES. The percentage SADS reduction in patients was correlated with getting lost ( r = 0.468, P < 0.0001), crashes ( P = 0.002), and centerline/road-edge excursions ( P = 0.01). There was a significantly higher percentage SADS reduction in cirrhotics who got lost (25%) compared to those who did not get lost (12%) and controls (8%, P = 0.014). Conclusions: Insight into driving skills in cirrhosis improves after driving simulation and is highest in those with navigation errors and MHE on ICT. Driving simulator-associated insight improvement may be the first step towards the cognitive rehabilitation of driving skills in cirrhosis. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
12. The Multi-Dimensional Burden of Cirrhosis and Hepatic Encephalopathy on Patients and Caregivers.
- Author
-
Bajaj, Jasmohan S, Wade, James B., Gibson, Douglas P., Heuman, Douglas M., Thacker, Leroy R., Sterling, Richard K., Stravitz, R. Todd, Luketic, Velimir, Fuchs, Michael, White, Melanie B., Bell, Debulon E., Gilles, HoChong, Morton, Katherine, Noble, Nicole, Puri, Puneet, and Sanyal, Arun J.
- Subjects
CIRRHOSIS of the liver ,SOCIOECONOMICS ,CAREGIVERS ,HEPATIC encephalopathy ,DEMOGRAPHIC surveys ,EMPLOYMENT ,COGNITIVE testing ,PATIENTS - Abstract
OBJECTIVES:Cirrhosis and hepatic encephalopathy (HE) can adversely affect survival, but their effect on socioeconomic and emotional burden on the family is not clear. The aim was to study the emotional and socioeconomic burden of cirrhosis and HE on patients and informal caregivers.METHODS:A cross-sectional study in two transplant centers (Veterans and University) of cirrhotic patients and their informal caregivers was performed. Demographics for patient/caregivers, model-for-end-stage liver disease (MELD) score, and cirrhosis complications were recorded. Patients underwent a cognitive battery, sociodemographic, and financial questionnaires. Caregivers were given the perceived caregiver burden (PCB; maximum=155) and Zarit Burden Interview (ZBI)-Short Form (maximum=48) and questionnaires for depression, anxiety, and social support.RESULTS:A total of 104 cirrhotics (70% men, 44% previous HE, median MELD 12, 49% veterans) and their caregivers (66% women, 77% married, relationship duration 32±14 years) were included. Cirrhosis severely impacted the family unit with respect to work (only 56% employed), finances, and adherence. Those with previous HE had worse unemployment (87.5 vs. 19%, P=0.0001) and financial status (85 vs. 61%, P=0.019) and posed a higher caregiver burden; PCB (75 vs. 65, P=0.019) and ZBI (16 vs. 11, P=0.015) compared with others. Cognitive performance and MELD score were significantly correlated with employment and caregiver burden. Veterans and non-veterans were equally affected. On regression, depression score, MELD, and cognitive tests predicted both PCB and ZBI score.CONCLUSIONS:Previous HE and cognitive dysfunction are associated with worse employment, financial status, and caregiver burden. Cirrhosis-related expenses impact the family unit's daily functioning and medical adherence. A multidisciplinary approach to address this burden is required. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
13. A Single Center Review of the Use of Mycophenolate Mofetil in the Treatment of Autoimmune Hepatitis.
- Author
-
Hlivko, Jonathan T., Shiffman, Mitchell L., Stravitz, R. Todd, Luketic, Velimir A., Sanyal, Arun J., Fuchs, Michael, and Sterling, Richard K.
- Subjects
CHRONIC active hepatitis ,IMMUNOSUPPRESSIVE agents ,PREDNISONE ,AUTOIMMUNE diseases ,FIBROSIS ,CIRRHOSIS of the liver ,DRUG side effects ,THERAPEUTICS - Abstract
Background & Aims: Standard treatment for autoimmune hepatitis (AIH) involves immune suppression by using prednisone alone or in combination with azathioprine (AZA). Although this regimen achieves remission in approximately 80%, some patients are intolerant or do not respond. Mycophenolate mofetil (MMF) is a potent immunosuppressant. However, its utility in AIH is not well-defined. Methods: We performed a retrospective longitudinal analysis of patients with AIH. Results: We identified 128 patients with AIH: mean age, 42.8 years; 83% female; 69% white. At presentation, median AST and ALT were 227 and 261 U/L, respectively, and bridging fibrosis and cirrhosis were present in 38% and 22%, respectively. Overall, 29 patients received MMF; 12 were switched to MMF after intolerance or nonresponse to prednisone ± AZA, whereas 17 received MMF ± prednisone as initial therapy. The main reasons for switching to MMF were nausea/vomiting (n = 4) and failure to normalize liver enzymes (n = 3). Ten of the 29 patients who received MMF therapy (34%) discontinued MMF as a result of side effects. Sixteen (84%) of the remaining 19 patients on MMF achieved remission, which closely matched the remission rate of those who remained on prednisone ± AZA (82%). The only independent clinical factor that predicted the eventual need for the use of MMF was absence of cirrhosis (P = .0067). Conclusions: (1) MMF was associated with a high rate of intolerance (34%). (2) In those who could tolerate it, it was associated with a high rate of remission (84%). (3) Absence of cirrhosis on presentation was the only independent factor associated with eventual need for MMF. [Copyright &y& Elsevier]
- Published
- 2008
- Full Text
- View/download PDF
14. The Role of the Transsulfuration Pathway in Non-Alcoholic Fatty Liver Disease.
- Author
-
Werge, Mikkel Parsberg, McCann, Adrian, Galsgaard, Elisabeth Douglas, Holst, Dorte, Bugge, Anne, Albrechtsen, Nicolai J. Wewer, Gluud, Lise Lotte, and Fuchs, Michael
- Subjects
NON-alcoholic fatty liver disease ,CIRRHOSIS of the liver ,HOMOCYSTEINE ,GLUTATHIONE ,WESTERN diet ,HIGH-calorie diet - Abstract
The prevalence of non-alcoholic fatty liver disease (NAFLD) is increasing and approximately 25% of the global population may have NAFLD. NAFLD is associated with obesity and metabolic syndrome, but its pathophysiology is complex and only partly understood. The transsulfuration pathway (TSP) is a metabolic pathway regulating homocysteine and cysteine metabolism and is vital in controlling sulfur balance in the organism. Precise control of this pathway is critical for maintenance of optimal cellular function. The TSP is closely linked to other pathways such as the folate and methionine cycles, hydrogen sulfide (H
2 S) and glutathione (GSH) production. Impaired activity of the TSP will cause an increase in homocysteine and a decrease in cysteine levels. Homocysteine will also be increased due to impairment of the folate and methionine cycles. The key enzymes of the TSP, cystathionine β-synthase (CBS) and cystathionine γ-lyase (CSE), are highly expressed in the liver and deficient CBS and CSE expression causes hepatic steatosis, inflammation, and fibrosis in animal models. A causative link between the TSP and NAFLD has not been established. However, dysfunctions in the TSP and related pathways, in terms of enzyme expression and the plasma levels of the metabolites (e.g., homocysteine, cystathionine, and cysteine), have been reported in NAFLD and liver cirrhosis in both animal models and humans. Further investigation of the TSP in relation to NAFLD may reveal mechanisms involved in the development and progression of NAFLD. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
15. Rifaximin Improves Driving Simulator Performance in a Randomized Trial of Patients With Minimal Hepatic Encephalopathy.
- Author
-
Bajaj, Jasmohan S., Heuman, Douglas M., Wade, James B., Gibson, Douglas P., Saeian, Kia, Wegelin, Jacob A., Hafeezullah, Muhammad, Bell, Debulon E., Sterling, Richard K., Stravitz, R. Todd, Fuchs, Michael, Luketic, Velimir, and Sanyal, Arun J.
- Subjects
ANTIBIOTICS testing ,HEPATIC encephalopathy ,CLINICAL trials ,COGNITIVE ability ,CIRRHOSIS of the liver ,INTERLEUKIN-10 ,HEALTH outcome assessment ,RANDOMIZED controlled trials ,THERAPEUTICS - Abstract
Background & Aims: Patients with cirrhosis and minimal hepatic encephalopathy (MHE) have driving difficulties but the effects of therapy on driving performance is unclear. We evaluated whether performance on a driving simulator improves in patients with MHE after treatment with rifaximin. Methods: Patients with MHE who were current drivers were randomly assigned to placebo or rifaximin groups and followed up for 8 weeks (n = 42). Patients underwent driving simulation (driving and navigation tasks) at the start (baseline) and end of the study. We evaluated patients'' cognitive abilities, quality of life (using the Sickness Impact Profile), serum levels of ammonia, levels of inflammatory cytokines, and model for end-stage-liver disease scores. The primary outcome was the percentage of patients who improved in driving performance, calculated as follows: total driving errors = speeding + illegal turns + collisions. Results: Over the 8-week study period, patients given rifaximin made significantly greater improvements than those given placebo in avoiding total driving errors (76% vs 31%; P = .013), speeding (81% vs 33%; P = .005), and illegal turns (62% vs 19%; P = .01). Of patients given rifaximin, 91% improved their cognitive performance, compared with 61% of patients given placebo (P = .01); they also made improvements in the psychosocial dimension of the Sickness Impact Profile compared with the placebo group (P = .04). Adherence to the assigned drug averaged 92%. Neither group had changes in ammonia levels or model for end-stage-liver disease scores, but patients in the rifaximin group had increased levels of the anti-inflammatory cytokine interleukin-10. Conclusions: Patients with MHE significantly improve driving simulator performance after treatment with rifaximin, compared with placebo. [Copyright &y& Elsevier]
- Published
- 2011
- Full Text
- View/download PDF
16. Liver-Unrelated Comorbid Conditions Do Not Affect Cognitive Performance or Hepatic Encephalopathy Progression in Cirrhosis.
- Author
-
Acharya, Chathur, Nadhem, Omar, Shaw, Jawaid, Hassouneh, Ramzi, Fagan, Andrew, McGeorge, Sara, Sterling, Richard K., Puri, Puneet, Fuchs, Michael, Luketic, Velimir, Sanyal, Arun J., Wade, James B., Gilles, HoChong S., Heuman, Douglas M., Tinsley, Felicia, Matherly, Scott, Lee, Hannah, Siddiqui, Mohammad S., Thacker, Leroy R., and Bajaj, Jasmohan S.
- Subjects
- *
HEPATIC encephalopathy , *CIRRHOSIS of the liver , *DISEASE progression , *HYPERTENSION , *MENTAL depression , *PROTON pump inhibitors - Abstract
INTRODUCTION: We aimed to determine the effect of comorbidities on covert hepatic encephalopathy (CHE) diagnosis and overt hepatic encephalopathy (OHE) development. METHODS: Cirrhotic outpatients underwent CHE testing and 2-year follow-up. Cox regression was performed for time to OHE. In total, 700 patients (60 years, 84%men, model for end-stage liver disease 11) and33% prior OHE underwent testing and follow-up. RESULTS: Major comorbidities were hypertension (54%), diabetes (35%), and depression (29%). Common medications were proton pump inhibitor (49%), beta-blockers (32%), and opioids (21%). Approximately 90 (40%) prior-OHE patients developed recurrence 93 (30,206) days post-testing predicted only by liverrelated variables. DISCUSSION: Demographics, cirrhosis characteristics, and opioid use, but not other comorbid conditions, were associated with CHE diagnosis and OHE progression. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
17. Sex is associated with differences in gut microbial composition and function in hepatic encephalopathy.
- Author
-
Saboo, Krishnakant, Shamsaddini, Amirhossein, Iyer, Mihir V., Hu, Chang, Fagan, Andrew, Gavis, Edith A., White, Melanie B., Fuchs, Michael, Heuman, Douglas M., Sikaroodi, Masoumeh, Iyer, Ravishankar K., Gillevet, Patrick M., and Bajaj, Jasmohan S.
- Subjects
- *
HEPATIC encephalopathy , *RANDOM forest algorithms , *PROTON pump inhibitors , *CIRRHOSIS of the liver , *LIVER diseases - Abstract
Altered microbiota can affect the gut-liver-brain axis in cirrhosis and hepatic encephalopathy (HE), but the impact of sex on these changes is unclear. We aimed to determine differences in fecal microbiota composition/functionality between men and women with cirrhosis and HE on differing treatments. Cross-sectional stool microbiome composition (16s rRNA sequencing) and microbial functional analyses were performed in men and women with cirrhosis, and controls. Patients with HE on rifaximin+lactulose (HE-Rif), patients with HE on lactulose only (HE-Lac) and those with cirrhosis without HE (No-HE) were compared to controls using random forest classifier. Men and women were also compared. A total of 761 individuals were included, 619 with cirrhosis (466 men, 153 women) and 142 controls (92 men, 50 women). Men were older and more frequently used proton pump inhibitors (PPIs), but model for end-stage liver disease score, No-HE (n = 319), HE-lac (n = 130) and HE-Rif (n = 170) proportions were similar. PPI/age-adjusted AUC of differentiation between controls vs. all cirrhosis, and controls vs. No-HE were higher within women than men, but the adjusted AUC for No-HE vs. HE-Rif was higher in men. Control vs. HE-Rif differentiation was similar across sexes. Men vs. women were different in all cirrhosis, No-HE and HE-Lac but not HE-Rif on PERMANOVA and AUC analyses. Autochthonous taxa decreased and pathobionts increased with disease progression regardless of sex. In men, Lactobacillaceae were higher in HE-Lac but decreased in HE-Rif, along with Veillonellaceae. Pathways related to glutamate and aromatic compound degradation were higher in men at all stages. Degradation of androstenedione, an estrogenic precursor, was lower in men vs. women in HE-Rif, likely enhancing feminization. There are differences in gut microbial function and composition between men and women with cirrhosis, which could be implicated in differential responses to HE therapies. Further studies linking these differences to sex-specific outcomes are needed. Patients with cirrhosis develop changes in their brain function, and men often develop feminization with disease progression. However, the interaction between sex, microbiota and disease severity is unclear. We found that as disease progressed in men, their microbial composition began to approach that observed in women, with changes in specific microbes that are associated with male hormone metabolism. • Patients with cirrhosis have variable responses to treatments for hepatic encephalopathy. • Men with cirrhosis demonstrate feminization but the role of microbiota is unclear. • Microbial changes between sexes are highest in compensated cirrhosis. • Changes in Lactobacillaceae and androgen metabolism differentiate between sexes. • Sex-microbiota interactions can influence feminization and response to treatments for hepatic encephalopathy. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
18. Differential impact of hyponatremia and hepatic encephalopathy on health-related quality of life and brain metabolite abnormalities in cirrhosis.
- Author
-
Ahluwalia, Vishwadeep, Wade, James B., Thacker, Leroy, Kraft, Kenneth A., Sterling, Richard K., Stravitz, R. Todd, Fuchs, Michael, Bouneva, Iliana, Puri, Puneet, Luketic, Velimir, Sanyal, Arun J., Gilles, HoChong, Heuman, Douglas M., and Bajaj, Jasmohan S.
- Subjects
- *
HYPONATREMIA , *HEPATIC encephalopathy , *QUALITY of life , *BRAIN abnormalities , *CIRRHOSIS of the liver , *COGNITION , *COMPARATIVE studies - Abstract
Background & Aims: Hyponatremia (HN) and hepatic encephalopathy (HE) together can impair health-related quality of life (HRQOL) and cognition in cirrhosis. We aimed at studying the effect of hyponatremia on cognition, HRQOL, and brain MR spectroscopy (MRS) independent of HE. Methods: Four cirrhotic groups (no HE/HN, HE alone, HN alone (sodium <130mEq/L), HE+HN) underwent cognitive testing, HRQOL using Sickness Impact Profile (SIP: higher score is worse; has psychosocial and physical sub-scores) and brain MRS (myoinositol (mI) and glutamate+glutamine (Glx)), which were compared across groups. A subset underwent HRQOL testing before/after diuretic withdrawal. Results: 82 cirrhotics (30 no HE/HN, 25 HE, 17 HE+HN, and 10 HN, MELD 12, 63% hepatitis C) were included. Cirrhotics with HN alone and without HE/HN had better cognition compared to HE groups (median abnormal tests no-HE/HN: 3, HN: 3.5, HE: 6.5, HE+HN: 7, p =0.008). Despite better cognition, HN only patients had worse HRQOL in total and psychosocial SIP while both HN groups (with/without HE) had a significantly worse physical SIP (p <0.0001, all comparisons). Brain MRS showed the lowest Glx in HN and the highest in HE groups (p <0.02). mI levels were comparably decreased in the three affected (HE, HE+HN, and HN) groups compared to no HE/HN and were associated with poor HRQOL. Six HE+HN cirrhotics underwent diuretic withdrawal which improved serum sodium and total/psychosocial SIP scores. Conclusions: Hyponatremic cirrhotics without HE have poor HRQOL despite better cognition than those with concomitant HE. Glx levels were lowest in HN without HE but mI was similar across affected groups. HRQOL improved after diuretic withdrawal. Hyponatremia has a complex, non-linear relationship with brain Glx and mI, cognition and HRQOL. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
19. Modulation of the fecal bile acid profile by gut microbiota in cirrhosis
- Author
-
Kakiyama, Genta, Pandak, William M., Gillevet, Patrick M., Hylemon, Phillip B., Heuman, Douglas M., Daita, Kalyani, Takei, Hajime, Muto, Akina, Nittono, Hiroshi, Ridlon, Jason M., White, Melanie B., Noble, Nicole A., Monteith, Pamela, Fuchs, Michael, Thacker, Leroy R., Sikaroodi, Masoumeh, and Bajaj, Jasmohan S.
- Subjects
- *
BILE acids , *GUT microbiome , *CIRRHOSIS of the liver , *CHENODEOXYCHOLIC acid , *CHOLIC acid , *SERUM , *LIQUID chromatography-mass spectrometry , *HEPATIC encephalopathy - Abstract
Background & Aims: The 7α-dehydroxylation of primary bile acids (BAs), chenodeoxycholic (CDCA) and cholic acid (CA) into the secondary BAs, lithocholic (LCA) and deoxycholic acid (DCA), is a key function of the gut microbiota. We aimed at studying the linkage between fecal BAs and gut microbiota in cirrhosis since this could help understand cirrhosis progression. Methods: Fecal microbiota were analyzed by culture-independent multitagged-pyrosequencing, fecal BAs using HPLC and serum BAs using LC–MS in controls, early (Child A) and advanced cirrhotics (Child B/C). A subgroup of early cirrhotics underwent BA and microbiota analysis before/after eight weeks of rifaximin. Results: Cross-sectional: 47 cirrhotics (24 advanced) and 14 controls were included. In feces, advanced cirrhotics had the lowest total, secondary, secondary/primary BA ratios, and the highest primary BAs compared to early cirrhotics and controls. Secondary fecal BAs were detectable in all controls but in a significantly lower proportion of cirrhotics (p <0.002). Serum primary BAs were higher in advanced cirrhotics compared to the rest. Cirrhotics, compared to controls, had a higher Enterobacteriaceae (potentially pathogenic) but lower Lachonospiraceae, Ruminococcaceae and Blautia (7α-dehydroxylating bacteria) abundance. CDCA was positively correlated with Enterobacteriaceae (r=0.57, p <0.008) while Ruminococcaceae were positively correlated with DCA (r=0.4, p <0.05). A positive correlation between Ruminococcaceae and DCA/CA (r=0.82, p <0.012) and Blautia with LCA/CDCA (r=0.61, p <0.03) was also seen. Prospective study: post-rifaximin, six early cirrhotics had reduction in Veillonellaceae and in secondary/primary BA ratios. Conclusions: Cirrhosis, especially advanced disease, is associated with a decreased conversion of primary to secondary fecal BAs, which is linked to abundance of key gut microbiome taxa. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
20. Asymmetric dimethylarginine is strongly associated with cognitive dysfunction and brain MR spectroscopic abnormalities in cirrhosis
- Author
-
Bajaj, Jasmohan S., Ahluwalia, Vishwadeep, Wade, James B., Sanyal, Arun J., White, Melanie B., Noble, Nicole A., Monteith, Pamela, Fuchs, Michael, Sterling, Richard K., Luketic, Velimir, Bouneva, Iliana, Stravitz, Richard T., Puri, Puneet, Kraft, Kenneth A., Gilles, HoChong, and Heuman, Douglas M.
- Subjects
- *
ASYMMETRIC dimethylarginine , *BRAIN abnormalities , *CIRRHOSIS of the liver , *MAGNETIC resonance imaging of the brain , *NITRIC-oxide synthase inhibitors , *HEPATIC encephalopathy - Abstract
Background & Aims: Asymmetric dimethylarginine (ADMA) is an inhibitor of nitric oxide synthase that accumulates in liver disease and may contribute to hepatic encephalopathy (HE). We aimed at evaluating the association of ADMA with cognition and brain MR spectroscopy (MRS) in cirrhosis. Methods: Cirrhotic patients with/without prior HE and non-cirrhotic controls underwent cognitive testing and ADMA determination. A subgroup underwent brain MRS [glutamine/glutamate (Glx), myoinositol (mI), N-acetyl-aspartate (NAA) in parietal white, occipital gray, and anterior cingulated (ACC)]. Cognition and ADMA in a cirrhotic subgroup before and one month after transjugular intrahepatic portosystemic shunting (TIPS) were also tested. Cognition and MRS values were correlated with ADMA and compared between groups using multivariable regression. ADMA levels were compared between those who did/did not develop post-TIPS HE. Results: Ninety cirrhotics (MELD 13, 54 prior HE) and 16 controls were included. Controls had better cognition and lower ADMA, Glx, and higher mI compared to cirrhotics. Prior HE patients had worse cognition, higher ADMA and Glx and lower mI compared to non-HE cirrhotics. ADMA was positively correlated with MELD (r=0.58, p<0.0001), abnormal cognitive test number (r=0.66, p<0.0001), and Glx and NAAA (white matter, ACC) and negatively with mI. On regression, ADMA predicted number of abnormal tests and mean Z-score independent of prior HE and MELD. Twelve patients underwent TIPS; 7 developed HE post-TIPS. ADMA increased post-TIPS in patients who developed HE (p= 0.019) but not in others (p= 0.89). Conclusions: A strong association of ADMA with cognition and prior HE was found independent of the MELD score in cirrhosis. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
21. THU194 - Gut microbiota are associated with minimal hepatic encephalopathy (MHE) in cirrhosis regardless of country of origin.
- Author
-
Torre, Aldo, Lara, Mayra Rojas, Fagan, Andrew, Gavis, Edith, Nandez, Ivvone Escalona, White, Melanie, McGeorge, Sara, De Leon Osorio, Omar, Sikaroodi, Masoumeh, Gillevet, Patrick, Fuchs, Michael, and Bajaj, Jasmohan S
- Subjects
- *
GUT microbiome , *HEPATIC encephalopathy , *COUNTRY of origin (Immigrants) , *CIRRHOSIS of the liver , *LIVER diseases - Published
- 2020
- Full Text
- View/download PDF
22. AS081 - Fecal microbial transplant reduces short-term cravings, improves quality of life and microbial diversity in cirrhosis and alcohol use disorder: a randomized, placebo-controlled, clinical trial.
- Author
-
Bajaj, Jasmohan S., Fagan, Andrew, Gavis, Edith, Fuchs, Michael, Puri, Puneet, Patel, Samarth, Davis, Brian, White, Melanie, Meador, Jill, Sikaroodi, Masoumeh, and Gillevet, Patrick
- Subjects
- *
ALCOHOLISM , *FECAL microbiota transplantation , *MICROBIAL diversity , *MICROORGANISMS , *CIRRHOSIS of the liver - Published
- 2020
- Full Text
- View/download PDF
23. FRI-108-Gut-derived GABA is strongly linked with cognitive impairment in cirrhosis.
- Author
-
Bajaj, Jasmohan S, Wu, Qinglong, Fagan, Andrew, Boonma, Prapaporn, Gavis, Edith, White, Melanie, Aravamudhanramanujam, Aiswarya, Fuchs, Michael, Yalcinkaya, Nazli, John, Binu, Haag, Anthony, and Savidge, Tor
- Subjects
- *
GABA , *CIRRHOSIS of the liver , *DISABILITIES - Published
- 2019
- Full Text
- View/download PDF
24. SAT140 - Salivary and stool microbiota differences are related to differences in 90-day hospitalizations in Mexican compared to American patients with cirrhosis.
- Author
-
Bajaj, Jasmohan S, Fagan, Andrew, Gavis, Edith, Sikaroodi, Masoumeh, Lara, Mayra Rojas, Nandez, Ivvone Escalona, De Leon Osorio, Omar, Fuchs, Michael, Gillevet, Patrick, Acharya, Chathur, and Torre, Aldo
- Subjects
- *
MEXICAN Americans , *CIRRHOSIS of the liver , *HOSPITAL care - Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.